Ayala Pharmaceuticals
Clinical-stage biopharmaceutical company dedicated to developing targeted cancer therapies.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor | €0.0 | round |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
$25.0m | Post IPO Equity | ||
| Total Funding | 000k | ||
| USD | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | 59 % | (5 %) | (80 %) | (98 %) |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (752 %) | (798 %) | (1114 %) | (5385 %) | (275915 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (762 %) | (813 %) | (1148 %) | (5493 %) | (369785 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 618 % | 604 % | 854 % | 4025 % | 185238 % |
Source: Company filings or news article
Related Content
Ayala Pharmaceuticals is a biopharmaceutical company focused on developing targeted therapies for patients with rare and aggressive cancers. The company leverages next-generation sequencing and a proprietary bioinformatics platform to pioneer novel approaches in cancer treatment. Ayala's primary focus is on the Notch pathway, a critical facilitator in cancer processes such as cellular proliferation, survival, migration, invasion, drug resistance, and metastatic spread. By inhibiting the Notch pathway with gamma-secretase inhibitors (GSIs) like AL101 and AL102, Ayala aims to turn off Notch pathway activation, thereby halting tumorigenesis and cancer progression.
Ayala serves patients suffering from rare cancers, a market often overlooked by larger pharmaceutical companies. The company's business model revolves around the development and commercialization of these targeted therapies. Revenue is generated through the sale of its proprietary drugs, partnerships, and potential licensing agreements.
Keywords: targeted therapies, rare cancers, Notch pathway, bioinformatics, next-gen sequencing, gamma-secretase inhibitors, AL101, AL102, tumorigenesis, cancer treatment.
